Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M – CDC

by

  1. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M CDC
  2. RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC STAT
  3. AstraZeneca, Sanofi’s Beyfortus 90% Effective at Preventing RSV Hospitalizations: CDC BioSpace
  4. New RSV vaccine 90% effective at preventing infant hospitalizations WXYZ 7 Action News Detroit
  5. CDC says new treatment for infant RSV infections ‘highly effective’ in preventing hospitalization WSB Atlanta

Read original article here

Leave a Comment